CRISPR

CRISPR1-bmp10

ID

ZDB-CRISPR-250609-2

Name

CRISPR1-bmp10

Previous Names

None

Target

bmp10 (1)

Sequence

5' - GGGTTGGATGATGGACATGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "AGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
sou20	bmp10

Expression

Gene expression in Wild Types + CRISPR1-bmp10

No data available

Phenotype

Phenotype resulting from CRISPR1-bmp10

No data available

Phenotype of all Fish created by or utilizing CRISPR1-bmp10

Phenotype	Fish	Conditions	Figures
blood plasma iron cation decreased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
intestine goblet cell amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
nucleate erythrocyte amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
whole organism decreased length, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1 from Hu et al., 2024
heart reactive oxygen species increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
heart ab4-map1lc3 labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
heart Ab2-gpx4 labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
whole organism viability, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1, Fig. 3 from Hu et al., 2024
hepatocyte vacuole increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 3 from Hu et al., 2024
heart Ab16-stat3 labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
intestine goblet cell decreased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 3 from Hu et al., 2024
heart Ab11-stat3 labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
heart Ab6-il6 labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
heart ptgs2a expression increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2, Fig. 3 from Hu et al., 2024
hepatocyte vacuole amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
heart ncoa4 expression increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
heart Ab1-slc40a1 labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
heart nppb expression amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
heart size, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
cardiac muscle cell disorganized, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1, Fig. 3 from Hu et al., 2024
heart malonaldehyde increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2, Fig. 3 from Hu et al., 2024
hepatocyte nucleus shape, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
intestinal mucosa morphology, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
heart iron cation increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2, Fig. 3 from Hu et al., 2024
cardiac ventricle cellular response to hypoxia increased process quality, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
heart Ab1-slc40a1 labeling decreased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
heart nppa expression increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1, Fig. 3 from Hu et al., 2024
heart Ab1-ferritin labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
blood plasma iron ion binding decreased process quality, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
heart increased size, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1, Fig. 3 from Hu et al., 2024
nucleate erythrocyte decreased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1, Fig. 3 from Hu et al., 2024
heart nppa expression amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
whole organism viability, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
nucleate erythrocyte amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by injection: ferric ammonium citrate	Fig. 3 from Hu et al., 2024
heart iron cation amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
heart iron cation decreased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 2 from Hu et al., 2024
intestinal mucosa morphology, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 3 from Hu et al., 2024
heart hamp expression increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
cardiac muscle cell organization quality, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
heart nppb expression increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1, Fig. 3 from Hu et al., 2024
hepatocyte nucleus shape, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 3 from Hu et al., 2024
heart ptgs2a expression amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024
heart Ab9-hif1a labeling increased amount, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 4 from Hu et al., 2024
blood desaturated red, abnormal	bmp10^sou20/sou20 (AB)	standard conditions	Fig. 1 from Hu et al., 2024
heart malonaldehyde amount, ameliorated	bmp10^sou20/sou20 (AB)	chemical treatment by environment: desferrioxamine B	Fig. 3 from Hu et al., 2024

Citations